Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bolt Biotherapeutics (BOLT) Current Assets (2020 - 2025)

Bolt Biotherapeutics' Current Assets history spans 6 years, with the latest figure at $35.6 million for Q3 2025.

  • For Q3 2025, Current Assets fell 37.69% year-over-year to $35.6 million; the TTM value through Sep 2025 reached $35.6 million, down 37.69%, while the annual FY2024 figure was $50.8 million, 51.93% down from the prior year.
  • Current Assets for Q3 2025 was $35.6 million at Bolt Biotherapeutics, down from $38.3 million in the prior quarter.
  • Across five years, Current Assets topped out at $271.2 million in Q1 2021 and bottomed at $35.6 million in Q3 2025.
  • The 5-year median for Current Assets is $130.7 million (2023), against an average of $134.0 million.
  • The largest annual shift saw Current Assets soared 645.87% in 2021 before it crashed 55.28% in 2025.
  • A 5-year view of Current Assets shows it stood at $189.2 million in 2021, then decreased by 8.68% to $172.7 million in 2022, then plummeted by 38.81% to $105.7 million in 2023, then tumbled by 51.93% to $50.8 million in 2024, then dropped by 29.93% to $35.6 million in 2025.
  • Per Business Quant, the three most recent readings for BOLT's Current Assets are $35.6 million (Q3 2025), $38.3 million (Q2 2025), and $42.5 million (Q1 2025).